AC Immune SA (ACIU)
| Market Cap | 267.22M |
| Revenue (ttm) | 1,087 |
| Net Income (ttm) | -74.17M |
| Shares Out | 83.53M |
| EPS (ttm) | -0.93 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 18,882 |
| Open | 3.20 |
| Previous Close | 3.20 |
| Day's Range | 3.03 - 3.21 |
| 52-Week Range | 1.68 - 3.83 |
| Beta | 0.72 |
| Analysts | Strong Buy |
| Price Target | 16.00 (+401.57%) |
| Earnings Date | Nov 3, 2023 |
About ACIU
AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. The company is developing Crenezumab, a humanized, conformation-specific monoclonal antibody, which is in Ph... [Read more]
Analyst Forecast
According to one analyst, the rating for ACIU stock is "Strong Buy" and the 12-month stock price forecast is $16.0.
News
AC Immune to Present at the Jefferies 2023 London Healthcare Conference
AC Immune to Present at the Jefferies 2023 London Healthcare Conference Lausanne, Switzerland, November 7, 2023 – AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering pre...
AC Immune Reports Third Quarter 2023 Financial Results and Provides a Corporate Update
AC Immune Reports Third Quarter 2023 Financial Results and Provides a Corporate Update Results from amyloid plaque reduction analysis (Abeta-PET) after 6 months of treatment with ACI-24.060 in ABATE P...
AC Immune to Host KOL Webinar on Amyloid Plaque PET Imaging in Alzheimer's Disease as a Surrogate of Clinical Efficacy on November 9, 2023
AC Immune to Host KOL Webinar on Amyloid Plaque PET Imaging in Alzheimer's Disease as a Surrogate of Clinical Efficacy on November 9, 2023
AC Immune Clinical Data Published in Nature Communications Show Alpha-Synuclein PET Tracer ACI-12589 Has Potential as Neurodegenerative Disease Diagnostic
PRESS RELEASE
AC Immune Announces Upcoming Presentations at the 16th CTAD Conference
AC Immune Announces Upcoming Presentations at the 16 th CTAD Conference
AC Immune to Present at the Jefferies 2023 CNS & Neuro Summit in October 2023
AC Immune to Present at the Jefferies 2023 CNS & Neuro Summit in October 2023 Lausanne, Switzerland, October 5, 2023 – AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneerin...
AC Immune to Present at the H.C. Wainwright 25th Annual Global Investment Conference in September 2023
AC Immune to Present at the H.C. Wainwright 25th Annual Global Investment Conference in September 2023
AC Immune Reports Second Quarter 2023 Financial Results and Provides a Corporate Update
AC Immune Reports Second Quarter 2023 Financial Results and Provides a Corporate Update
AC Immune to Present at the BTIG Virtual Biotechnology Conference 2023
AC Immune to Present at the B TIG Virtual Biotechnology Conference 2023
AC Immune SA Appoints New Chief Medical Officer
AC Immune SA Appoints New Chief Medical Officer Nuno Mendonça, MD appointed new Chief Medical Officer and Executive Committee member Lausanne, Switzerland, July 2 6 , 202 3 – AC Immune SA (NASDAQ: ACI...
AC Immune Showcasing Precision Medicine Programs at AAIC 2023
AC Immune Showcas ing Precision Medicine P rograms at A AIC 202 3
AC Immune's stock soars 13% after FDA grants fast-track designation to Alzheimer's treatment
AC Immune SA's stock ACIU, +4.21% soared 13% premarket Tuesday, after the Swiss-based biotech said it has received U.S. Food and Drug Administration fast-track designation for an Alzheimer's disease t...
AC Immune Receives FDA Fast Track Designation for Anti-Amyloid-beta Active Immunotherapy, ACI-24.060, to Treat Alzheimer's Disease
AC Immune Receives FDA Fast Track Designation for Anti-Amyloid- beta Active Immunotherapy , ACI-24.060, to Treat Alzheimer's Disease
AC Immune Holds Annual General Meeting of Shareholders
AC Immune Holds Annual General Meeting of Shareholders Shareholders approved all resolutions as proposed by the Board of Directors Lausanne, Switzerland, June 23, 2023 – AC Immune SA (NASDAQ: ACIU), a...
AC Immune Reports First Quarter 2023 Financial Results and Provides a Corporate Update
AC Immune Reports First Quarter 2023 Financial Results and Provides a Corporate Update ACI-24.060 anti-Abeta vaccine showed positive initial safety and immunogenicity in first Alzheimer's disease (AD)...
AC Immune to Host Key Opinion Leader Webinar on Early Diagnosis and Prevention of Alzheimer's Disease
AC Immune to Host Key Opinion Leader Webinar on Early Diagnosis and Prevention of Alzheimer's Disease
AC Immune at AD/PD™ 2023 to Present New Clinical and Preclinical Data from its Precision Medicine Pipeline
AC Immune at AD/PD ™ 202 3 to Present New Clinical and Preclinical Data f rom its Precision Medicine Pipeline
AC Immune Reports Full Year 2022 Financial Results and Provides Corporate Update
AC Immune Reports Full Year 2022 Financial Results and Provides Corporate Update
AC Immune to Report Full Year 2022 Financial Results and Provide Corporate Update on March 16, 2023
AC Immune to Report Full Year 2022 Financial Results and Provide Corporate Update on March 16, 2023
AC Immune Awarded New Grants from MJFF and Target ALS Supporting Programs Targeting TDP-43
AC Immune Awarded New Grants from MJFF and Target ALS Supporting Programs Targeting TDP-43
AC Immune to Present at the SVB Securities Global Biopharma Conference
AC Immune to Present at the SVB Securities Global Biopharma Conference
AC Immune's ACI-24.060 Anti-Amyloid Beta Vaccine for Alzheimer's Shows Positive Initial Interim Safety and Immunogenicity in Phase 1b/2 ABATE Trial
AC Immune's ACI-24.060 Anti-Amyloid Beta Vaccine for Alzheimer's Shows Positive Initial Interim Safety and Immunogenicity in Phase 1b/2 ABATE Trial
AC Immune Partner Life Molecular Imaging Initiates Phase 3 Study of Tau PET Diagnostic PI-2620 for Alzheimer's Disease
AC Immune Partner Life Molecular Imaging Initiates Phase 3 S tudy of Tau PET Diagnostic PI - 2620 for Alzheimer's Disease
AC Immune's Alzheimer's Disease Vaccine-candidate ACI-35.030 Selected for Further Development
AC Immune 's Alzheimer's Disease Vaccine-candidate ACI-35.030 S elect ed for Further Development
AC Immune to Present Progress of Alzheimer's Disease Programs targeting Abeta and Tau at the 15th CTAD Conference
Lausanne, Switzerland, November 2 3 , 202 2 – AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced the ...